Bell Potter analyst, John Hester, has amended his recommendation of Resmed (RMD) from a BUY to HOLD

Bell Potter


Bell Potter analyst, John Hester, has amended his recommendation of Resmed (RMD) from a BUY to HOLD. The 1.8% earnings downgrade in FY14 is a consequence of the lower than expected gross margin result of 63.3% which was 70bps below our forecast and 140bps below the previous sequential quarter. In our view, even though volumes may continue to grow strongly the pricing pressure is likely to be ongoing. New products no longer attract the pricing premium they once did and other pricing pressures are ongoing and this follows a step adjustment in pricing over the last 90 days. Considering the modest forecast EPS growth in FY15 and following the share price bounce that resulted from this latest earnings announcement, we have amended our recommendation from BUY to HOLD.

Bell Potter Securities is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to a diversified client base that includes individuals, institutions and corporations.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.